Groundbreaking research from Cincinnati Children’s Hospital challenges conventional understanding of neurofibromatosis type 1 (NF1) pain mechanisms. Scientists have discovered that chronic pain in NF1 patients originates at the cellular level, driven by abnormal Schwann cell signaling rather than solely from tumor growth compressing nerves.
The research team identified that Schwann cells in NF1 patients produce abnormally elevated levels of glial cell line-derived neurotrophic factor (GDNF)—approximately 285% higher than normal levels. This excess GDNF heightens pain signaling pathways even before characteristic neurofibromas develop along nerve tissues.
Using mouse models with NF1 mutations, researchers demonstrated how aberrant GDNF signaling creates hypersensitivity to pain stimuli. This mechanistic insight explains why some patients experience debilitating chronic pain before visible tumors appear, opening new avenues for targeted therapeutic interventions beyond traditional tumor-focused treatments.
Read the full article on GMJ Newsroom.
Was this article helpful?
